에피네프린 자동 주사기 시장 예측(-2030년) : 제품별, 투여량별, 연령층별, 브랜드별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Epinephrine Auto-Injectors Market is accounted for $2.33 billion in 2024 and is expected to reach $3.37 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Epinephrine auto-injectors are medical devices designed for emergency self-administration of epinephrine, a life-saving medication used to treat severe allergic reactions (anaphylaxis). These compact, portable devices contain a pre-measured dose of epinephrine and feature a spring-loaded mechanism for rapid injection into the thigh muscle. They provide quick relief by constricting blood vessels, relaxing airway muscles, and reversing symptoms like swelling, low blood pressure, and breathing difficulties. Commonly used by individuals with severe allergies, they are essential for immediate response during life-threatening allergic emergencies.

According to World Health Organization reports, over 16 billion injections were administered annually worldwide in 2021, stimulated by the increasing number of injections administered boosting the auto injector market.

Market Dynamics:

Driver:

Rising prevalence of anaphylaxis

The number of cases of severe allergic responses rises; the necessity for quick treatment alternatives becomes increasingly important. Epinephrine auto-injectors provide a fast and convenient way to administer life-saving medication in emergencies. Growing awareness about anaphylaxis and its risks has led to a heightened demand for these devices. The market is further fuelled by advancements in auto-injector technology, offering user-friendly designs. With an expanding at-risk population, epinephrine auto-injectors are becoming an essential tool for managing anaphylaxis, ensuring a sustained market growth.

Restraint:

Product recalls and malfunctions

Product recalls and malfunctions like failed delivery of auto-injectors to accurate doses during emergencies, it poses severe health risks, deterring users from relying on them. Recalls disrupt the supply chain and create shortages, leaving patients without access to critical medical devices. Additionally, recalls often lead to increased regulatory scrutiny, delaying new product approvals and market expansions. The financial burden of recalls and associated lawsuits also impacts manufacturers, limiting their ability to invest in innovation.

Opportunity:

Expansion of indications

The new medical conditions, such as food allergies and insect stings, are identified as requiring immediate epinephrine treatment, the demand for auto-injectors rises. Additionally, healthcare organizations are increasingly recognizing the importance of carrying auto-injectors for emergency use, further increasing their adoption. This broader usage across various demographics enhances market reach. Advancements in formulation and device design also contribute to greater patient compliance and ease of use. Ultimately, the expanded indications improve awareness and access, driving higher market penetration and sales.

Threat:

Legal and ethical concerns

High prices of auto-injectors, often attributed to patent protections, raise ethical questions about accessibility, especially for low-income patients. Regulatory hurdles and lawsuits over pricing and monopolistic practices create a challenging legal environment for manufacturers. Ethical concerns also arise from a lack of generic alternatives, limiting affordability and market competition. Liability issues related to device malfunctions or incorrect usage further deter innovation and investment. These factors collectively hinder the market's growth and broader adoption of life-saving auto-injectors.

Covid-19 Impact

The COVID-19 pandemic significantly impacted the epinephrine auto-injectors market. Disruptions in supply chains, reduced patient visits to healthcare facilities, and delayed elective treatments initially hindered market growth. However, the heightened focus on respiratory health and self-care led to increased demand for at-home treatment solutions, benefiting the market. Telemedicine and online pharmacies emerged as key distribution channels during lockdowns. Manufacturers adapted by ramping up production and ensuring accessibility. The market demonstrated resilience, with gradual recovery aligning with improved healthcare access and the normalization of supply chains post-pandemic.

The single-dose auto-injectors segment is expected to be the largest during the forecast period

The single-dose auto-injectors segment is estimated to have a lucrative growth, by offering convenience and ease of use for individuals facing severe allergic reactions. These devices provide quick, self-administered doses, ensuring timely epinephrine delivery in emergencies. They are designed for portability, making them suitable for on-the-go use, which increases their adoption rates. Furthermore, regulatory approvals and innovations in design have enhanced the accessibility and effectiveness of single-dose auto-injectors. As a result, this segment continues to contribute significantly to the growth of the overall market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, due to immediate access to life-saving treatment for anaphylactic emergencies. Hospitals often serve as the primary setting for patients experiencing severe allergic reactions, where rapid administration of epinephrine is critical. With increasing allergic reactions globally, hospitals are stocking more auto-injectors to meet emergency needs. Additionally, healthcare professionals' awareness and training in using epinephrine auto-injectors drive their adoption in hospitals.

Region with largest share:

Asia Pacific is expected to hold the largest market share during the forecast period due to rising awareness of anaphylaxis and its management, coupled with increasing prevalence of food allergies and other severe allergic reactions. Countries like China, India, and Japan are seeing growing demand due to improved healthcare access and government initiatives promoting allergy management. Technological advancements in auto-injector design, such as compact and user-friendly devices, are also boosting adoption. Additionally, rising investments by pharmaceutical companies and collaborations for local manufacturing are enhancing availability and affordability across the region.

Region with highest CAGR:

North America is expected to have the highest CAGR over the forecast period, owing to increasing prevalence of anaphylactic reactions and allergies. Rising awareness about emergency treatment for allergic reactions and the need for quick medical intervention are boosting demand. The U.S. dominates the market due to high adoption rates, healthcare infrastructure, and the availability of various brands like EpiPen and Auvi-Q. Regulatory support, along with expanding insurance coverage, is further propelling the market.

Key players in the market

Some of the key players profiled in the Epinephrine Auto-Injectors Market include Viatris Inc., Amneal Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Kaleo, Inc., Pfizer, Inc., Sanofi S.A., Adamis Pharmaceuticals Corporation, Novartis International AG, Bausch Health Companies Inc., ALK-Abello A/S, Hikma Pharmaceuticals PLC, Antares Pharma, Inc., Meridian Medical Technologies, Inc., Becton, Dickinson and Company and Ypsomed Holding AG.

Key Developments:

In October 2024, Viatris entered into an exclusive licensing agreement to acquire rights to sotagliflozin in all markets outside the U.S. and Europe. The partnership aims to enhance the commercial reach of sotagliflozin, which is relevant for patients with diabetes and heart failure.

In February 2024, Viatris announced a significant global research and development collaboration with Idorsia Ltd. The collaboration aims to leverage Viatris' infrastructure alongside Idorsia's drug development capabilities.

Products Covered:

• Single-dose Auto-Injectors
• Multi-dose Auto-Injectors

Dosages Covered:

• 0.15 mg
• 0.3 mg
• Other Dosages

Age Groups Covered:

• 0-4 Years
• 5-14 Years
• 15-24 Years
• 25-49 Years
• 50-64 Years
• Above 65 Years
• Other Age Groups

Brands Covered:

• EpiPen (Mylan/Viatris)
• Auvi-Q (Kaleo)
• Adrenaclick (Amphastar Pharmaceuticals)
• Generic Versions
• Other Brands

Applications Covered:

• Anaphylaxis
• Food Allergies
• Drug Allergies
• Other Applications

End Users Covered:

• Hospitals
• Clinics
• Homecare Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Epinephrine Auto-Injectors Market, By Product

• 5.1 Introduction
• 5.2 Single-dose Auto-Injectors
• 5.3 Multi-dose Auto-Injectors

6 Global Epinephrine Auto-Injectors Market, By Dosage

• 6.1 Introduction
• 6.2 0.15 mg
• 6.3 0.3 mg
• 6.4 Other Dosages

7 Global Epinephrine Auto-Injectors Market, By Age Group

• 7.1 Introduction
• 7.2 0-4 Years
• 7.3 5-14 Years
• 7.4 15-24 Years
• 7.5 25-49 Years
• 7.6 50-64 Years
• 7.7 Above 65 Years
• 7.8 Other Age Groups

8 Global Epinephrine Auto-Injectors Market, By Brand

• 8.1 Introduction
• 8.2 EpiPen (Mylan/Viatris)
• 8.3 Auvi-Q (Kaleo)
• 8.4 Adrenaclick (Amphastar Pharmaceuticals)
• 8.5 Generic Versions
• 8.6 Other Brands

9 Global Epinephrine Auto-Injectors Market, By Application

• 9.1 Introduction
• 9.2 Anaphylaxis
• 9.3 Food Allergies
• 9.4 Drug Allergies
• 9.5 Other Applications

10 Global Epinephrine Auto-Injectors Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Clinics
• 10.4 Homecare Settings
• 10.5 Other End Users

11 Global Epinephrine Auto-Injectors Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Viatris Inc.
• 13.2 Amneal Pharmaceuticals, Inc.
• 13.3 Teva Pharmaceutical Industries Ltd.
• 13.4 Kaleo, Inc.
• 13.5 Pfizer, Inc.
• 13.6 Sanofi S.A.
• 13.7 Adamis Pharmaceuticals Corporation
• 13.8 Novartis International AG
• 13.9 Bausch Health Companies Inc.
• 13.10 ALK-Abello A/S
• 13.11 Hikma Pharmaceuticals PLC
• 13.12 Antares Pharma, Inc.
• 13.13 Meridian Medical Technologies, Inc.
• 13.14 Becton, Dickinson and Company
• 13.15 Ypsomed Holding AG